Last updated: May 29, 2026

Application No. 16/586,318

CROSS-SPECIES-SPECIFIC BISPECIFIC BINDERS

Final Rejection

Filed

Sep 27, 2019

Priority

Apr 03, 2007 — EU 07006988.5 +10 more

Examiner

SKELDING, ZACHARY S

Art Unit

1644

Tech Center

1600 — Biotechnology & Organic Chemistry

Assignee

Amgen Research (Munich) GmbH

OA Round

5 (Final)

This examiner grants 60% of cases after interview

— +41.5% interview lift. A telephonic interview to clarify the technical implementation could significantly improve the outcome.

Based on 823 resolved cases, 2023–2026

Examiner Intelligence

SKELDING, ZACHARY S View full profile →

Grants 60% of resolved cases

Career Allowance Rate

493 granted / 823 resolved

At TC average

Strong +42% interview lift

Without

With

+41.5%

Interview Lift

resolved cases with interview

Typical timeline

3y 7m

Avg Prosecution

29 currently pending

Career history

851

Total Applications

across all art units

Statute-Specific Performance

§101

1.8%

-38.2% vs TC avg

§103

33.1%

-6.9% vs TC avg

§102

10.0%

-30.0% vs TC avg

§112

35.1%

-4.9% vs TC avg

Black line = Tech Center average estimate • Based on career data from 823 resolved cases

Prosecution Timeline

Show 3 earlier events

Dec 13, 2023

Non-Final Rejection mailed

Jun 11, 2024

Response Filed

Sep 19, 2024

Final Rejection mailed

Mar 19, 2025

Request for Continued Examination

Mar 23, 2025

Response after Non-Final Action

May 29, 2025

Non-Final Rejection mailed

Nov 26, 2025

Response Filed

Dec 12, 2025

Final Rejection mailed (current)

Precedent Cases

Applications granted by this same examiner with similar technology

18/174,928

Patent 12630802

METHODS OF ISOLATING T CELLS AND T CELL RECEPTORS HAVING ANTIGENIC SPECIFICITY FOR A CANCER-SPECIFIC MUTATION FROM PERIPHERAL BLOOD

3y 2m to grant Granted May 19, 2026

17/791,056

Patent 12617860

ANTI-TNFR2 ANTIBODY AND USES THEREOF

3y 10m to grant Granted May 05, 2026

18/055,932

Patent 12617865

COMPOSITIONS AND METHODS RELATED TO TUMOR ACTIVATED ANTIBODIES TARGETING PSMA AND EFFECTOR CELL ANTIGENS

3y 5m to grant Granted May 05, 2026

17/511,218

Patent 12612458

ANTI-ALPHABETATCR ANTIBODY

4y 6m to grant Granted Apr 28, 2026

17/779,711

Patent 12612444

T CELL RECEPTORS TARGETING MUTATIONS IN RNA SPLICING FACTORS

3y 11m to grant Granted Apr 28, 2026

Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.

Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

6-7

Expected OA Rounds

60%

Grant Probability

99%

With Interview (+41.5%)

3y 7m (~0m remaining)

Median Time to Grant

High

PTA Risk

Based on 823 resolved cases by this examiner. Grant probability derived from career allowance rate.